Related Experiment Video
Updated: Sep 7, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
Prevention of deep venous thrombosis in orthopedic surgery: effects of defibrotide
R Zanasi1, G Fioretta, G Ciocia
1Orthopedics Department, Fatebenefratelli Hospital, Milan, Italy.
Insights
Defibrotide showed a promising trend in preventing symptomatic deep venous thrombosis (DVT) and pulmonary embolism after orthopedic surgery compared to calcium heparin and aspirin (ASA). This suggests defibrotide is a viable alternative for DVT prophylaxis.
Area of Science:
- Orthopedic Surgery
- Vascular Medicine
- Pharmacology
Background:
- Deep venous thrombosis (DVT) is a significant risk following orthopedic surgery.
- Current prophylactic measures include calcium heparin and acetylsalicylic acid (ASA).
- Novel therapeutic strategies are being explored to improve DVT prevention.
Purpose of the Study:
- To compare the efficacy of defibrotide against calcium heparin and ASA in preventing DVT post-orthopedic surgery.
- To evaluate the incidence of symptomatic DVT and pulmonary embolism in patients receiving different prophylactic treatments.
Main Methods:
- A randomized controlled trial involving 63 patients undergoing hip or other orthopedic surgery.
- Patients were assigned to receive defibrotide, calcium heparin, or ASA for DVT prophylaxis.
- Fibrinogen uptake tests were used for daily monitoring, alongside clinical assessment for DVT and pulmonary embolism.
Main Results:
- No significant difference in fibrinogen uptake was observed across the three treatment groups.
- Defibrotide demonstrated a trend towards lower rates of symptomatic DVT (1/19) compared to calcium heparin (2/25) and ASA (4/19).
- Defibrotide showed no cases of pulmonary embolism, while calcium heparin had one and ASA had two.
Conclusions:
- Defibrotide therapy presents a valid alternative for deep venous thrombosis prophylaxis in orthopedic surgery patients.
- The findings suggest a potential benefit of defibrotide in reducing symptomatic DVT and pulmonary embolism.
- Further research may be warranted to confirm the efficacy of defibrotide in this patient population.
Abstract:
The effectiveness of defibrotide was compared with that of calcium heparin and acetylsalicylic acid (ASA) in the prevention of deep venous thrombosis (DVT) resulting from orthopedic surgery. Sixty-three patients scheduled for elective or traumatological surgery, for the most part involving the hip joint, were recruited. The patients were randomly assigned to one of the following treatment groups: defibrotide (400 mg twice daily), administered intramuscularly (n = 19); calcium heparin (5,000 IU thrice daily), administered subcutaneously (n = 25); and ASA (100 mg on alternate days), administered orally (n = 19). Administration of the drug was started one day before surgery and continued until the seventh day after surgery. Each patient was monitored daily by means of the fibrinogen uptake test. The incidence of increased uptake did not differ significantly in the three groups (defibrotide, ten out of 19; calcium heparin, ten out of 25; ASA, seven out of 19). Conversely, a trend in favor of defibrotide was noted in cases of symptomatic DVT (defibrotide, one out of 19; calcium heparin, two out of 25; ASA, four out of 19) and pulmonary embolism (defibrotide, no cases; calcium heparin, one case; ASA two cases). On the strength of these findings, defibrotide therapy qualifies as a valid alternative to conventional DVT prophylaxis in orthopedic surgery.
Related Concept Videos
Peripheral Artery Disease IV: Nursing Management
Peripheral Artery Disease V: Postoperative Nursing Management
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management

